These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 9853996)

  • 21. Anodic coulometric detection with a glassy carbon electrode in combination with reversed-phase high-performance liquid chromatography. Determination of blood levels of perphenazine and fluphenazine.
    Tjaden UR; Lankelma J; Poppe H
    J Chromatogr; 1976 Sep; 125(1):275-86. PubMed ID: 977680
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Determination of basic drugs in blood by RP-HPLC].
    Zhuo X; Wu H; Liu W; Huang Z
    Fa Yi Xue Za Zhi; 1997; 13(4):203-4, 253-4. PubMed ID: 10375835
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Urinary excretion of perphenazine and its sulfoxide during administration in oral and long-acting injectable form.
    van Kempen GM
    Psychopharmacologia; 1971; 21(3):283-6. PubMed ID: 5095416
    [No Abstract]   [Full Text] [Related]  

  • 24. Perphenazine decanoate vs. perphenazine enanthate: efficacy and side effects in a 6 week double-blind, comparative study of 50 drug monitored psychotic patients.
    Knudsen P; Hansen LB; Auken G; Waehrens J; Højholdt K; Larsen NE
    Acta Psychiatr Scand Suppl; 1985; 322():15-28. PubMed ID: 3907278
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasma concentrations of perphenazine and its sulphoxide metabolite during continuous oral treatment.
    Hansen LB; Larsen NE
    Psychopharmacology (Berl); 1977 Jul; 53(2):127-30. PubMed ID: 408838
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term depot neuroleptic treatment with perphenazine decanoate. I. Efficacy and side effects in a 12 month study of 42 drug monitored psychotic patients.
    Knudsen P; Hansen LB; Højholdt K; Larsen NE
    Acta Psychiatr Scand Suppl; 1985; 322():29-40. PubMed ID: 3907279
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Therapy control of perphenazine. 2. Clinical aspects].
    Kjeldsen CS; Larsen NE; Kragh-Sørensen P; Andersen E; Brøsen K; Gerholt F; Glue P; Hørder M; Klitgaard NA; Krarup G
    Ugeskr Laeger; 1991 Aug; 153(34):2339-43. PubMed ID: 1897043
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drug-protein interactions: evaluation of the binding of antipsychotic drugs to glutamate dehydrogenase by quantitative affinity chromatography.
    Veronese FM; Bevilacqua R; Chaiken IM
    Mol Pharmacol; 1979 Mar; 15(2):313-21. PubMed ID: 38392
    [No Abstract]   [Full Text] [Related]  

  • 29. Spectrophotometric determination of perphenazine with the detection system of potassium ferricyanide-Fe(III) in pharmaceutical and serum samples.
    Guo L; Zhang Y; Li Q
    Spectrochim Acta A Mol Biomol Spectrosc; 2009 Oct; 74(2):307-11. PubMed ID: 19586796
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Pharmacokinetic profile of perphenazine enanthate].
    Viala A
    Encephale; 1976; 2(3):273-82. PubMed ID: 991807
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Carbamazepine interference in a high-performance liquid chromatography analysis for perphenazine.
    Spigset O; Carleborg L; Mjörndal T; Norström A; Sundgren M
    Ther Drug Monit; 1994 Jun; 16(3):332-3. PubMed ID: 8085288
    [No Abstract]   [Full Text] [Related]  

  • 32. Pharmacokinetics of orally disintegrating tablets of perphenazine/hydroxypropyl-beta-cyclodextrin inclusion complex in rabbits.
    Wang L; Xiao YY; Chen ML; Zeng F; Zong L
    Pharmazie; 2013 Oct; 68(10):800-4. PubMed ID: 24273883
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A mutual prodrug ester of GABA and perphenazine exhibits antischizophrenic efficacy with diminished extrapyramidal effects.
    Nudelman A; Gil-Ad I; Shpaisman N; Terasenko I; Ron H; Savitsky K; Geffen Y; Weizman A; Rephaeli A
    J Med Chem; 2008 May; 51(9):2858-62. PubMed ID: 18363346
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of the human cytochrome P450 isoforms mediating in vitro N-dealkylation of perphenazine.
    Olesen OV; Linnet K
    Br J Clin Pharmacol; 2000 Dec; 50(6):563-71. PubMed ID: 11136295
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Serum level of perphenazine determines by liquid chromatography].
    Dessalles MC; Vienne B; Mahuzier G
    J Chromatogr; 1989 Jan; 487(1):215-20. PubMed ID: 2715269
    [No Abstract]   [Full Text] [Related]  

  • 36. The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixol.
    Jerling M; Dahl ML; Aberg-Wistedt A; Liljenberg B; Landell NE; Bertilsson L; Sjöqvist F
    Clin Pharmacol Ther; 1996 Apr; 59(4):423-8. PubMed ID: 8612387
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Steady-state serum concentrations of the neuroleptic perphenazine in relation to CYP2D6 genetic polymorphism.
    Linnet K; Wiborg O
    Clin Pharmacol Ther; 1996 Jul; 60(1):41-7. PubMed ID: 8689810
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acute neuroleptic treatment in elderly patients without dementia.
    Mazure CM; Nelson JC; Jatlow PI; Bowers MB
    Am J Geriatr Psychiatry; 1998; 6(3):221-9. PubMed ID: 9659955
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plasma levels of perphenazine and its major metabolites during simultaneous treatment with anticholinergic drugs.
    Hansen LB; Elley J; Christensen TR; Larsen NE; Naestoft J; Hvidberg EF
    Br J Clin Pharmacol; 1979 Jan; 7(1):75-80. PubMed ID: 760745
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tissue accumulation of metabolites during chronic administration of piperazine-substituted phenothiazine drugs.
    Breyer U; Gaertner HJ
    Adv Biochem Psychopharmacol; 1974; 9(0):167-73. PubMed ID: 4151761
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.